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Differential  proﬁle  of  CDKN1A  and  TP53
expressions in bone  marrow  mesenchymal
pstromal cells  from  myeloid  neo
Dear Editor,
Attention has been increasing focused on the role of
the bone marrow microenvironment in the pathogenesis
and progression of hematological malignancies, includ-
ing myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML).1–3 Thus, the identiﬁcation of genes or pro-
teins that are differentially expressed in the abnormal bone
marrow niche may provide new therapeutic opportunities and
perspectives on the biology of these diseases. In a recent
report by Fei et al.,4 bone marrow mesenchymal stromal
cells (BMMSCs) from MDS  patients presented an upregula-
tion of p21 and p53 expressions, suggesting that activation
of this pathway may contribute to the senescent behavior
of these cells.4 In contrast, another study that also ana-
lyzed the expression proﬁle of senescence-related genes in
BMMSCs from MDS  and healthy donors observed a down-
regulation of CDKN1A expression, but no modulation in TP53
expression.5
To provide additional evidence on p21 and p53 expres-
sion in MDS  BMMSCs, we  veriﬁed the expression of these
genes in a cohort of eight healthy donors with median age
of 45 years (range: 28–57), 23 MDS  patients with median
age of 70 years (range: 16–90), seven AML patients with
myelodysplasia-related changes (AML-MRC) with median age
of 69 years (range: 30–86) and 12 de novo AML  cases accord-
ing to the WHO  2008 classiﬁcation, with median age of
61 years (range: 44–82).6 The MDS  group was comprised of
one refractory cytopenia with unilineage dysplasia (RCUD),
four refractory anemia with ringed sideroblasts (RARS), 12
refractory cytopenia with multilineage dysplasia (RCMD), two
refractory anemia with excess blast-1 (RAEB-1) and four
refractory anemia with excess blast-2 (RAEB-2). Bone mar-
row mononuclear cells were isolated by Ficoll-Hypaque plus
density-gradient centrifugation (GE Healthcare, Uppsala, Swe-
den) and cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM; Gibco, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS), penicillin/streptomycin andlasms
maintained at 37 ◦C, normoxia with 5% CO2. After the fourth
passage, all patient and control-derived BMMSCs presented
a homogeneous cell population (negative for CD31, CD34,
CD45 and HLA-DR, and positive for CD73, CD90 and CD105),
conﬁrming their mesenchymal origin, according to the Inter-
national Society for Cellular Therapy.7 Next, these samples
were used for gene expression analysis by quantitative poly-
merase chain reaction (qPCR) in a ABI 7500 Sequence Detection
System (Applied Biosystem, Foster City, CA, USA) using
speciﬁc primers for CDKN1A (p21 – FW: TGTCACTGTCTTG-
TACCCTTGT; RV: GCCGGCGTTTGGAGTGGTAG), TP53 (p53 –
FW: GGCGCACAGAGGAAGAGAAT; RV: GGAGAGGAGCTGGT-
GTTGTTG), and HPRT1 (FW: GAACGTCTTGCTCGAGATGTGA;
RV: TCCAGCAGGTCAGCAAAGAAT). The relative gene expres-
sion was calculated using the equation, 2−CT.8 Statistical
analyses were performed by ANOVA and Bonferroni post-test
using GraphPad Prism 5 (GraphPad Software, Inc., San Diego,
CA, USA); a p-value <0.05 was considered statistically signiﬁ-
cant.
In our cohort, BMMSCs from de novo AML  presented
increased CDKN1A mRNA  levels compared to healthy donors,
MDS and AML-MRC patients (p-value <0.05; Figure 1A).
TP53 expression was also higher in de novo AML  compared
to healthy donors and AML-MRC patients (p-value <0.05;
Figure 1B). However, we observed no differences in CDKN1A
and TP53 mRNA  levels in BMMSCs from MDS  and AML-
MRC patients compared to healthy donors (p-value >0.05;
Figure 1). When MDS  patients were stratiﬁed by the WHO
2008 classiﬁcation, no differences were observed between
RCUD/RARS/RCMD, RAEB-1/RAEB-2, AML-MRC and healthy
donors (p-value >0.05; Figure 1).
Existing data on MDS-derived BMMSC biology are some-
what controversial, reﬂecting differences in methodologies
and the heterogeneity of patients.9 There is evidence that
different culture media can signiﬁcantly inﬂuence the pheno-
type of mesenchymal cells.10,11 Thus, the lack of optimization
of cell isolation techniques and expansion conditions may
inﬂuence the gene expression proﬁle and the identiﬁcation of
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Figure 1 – CDKN1A and TP53 expression in bone marrow mesenchymal stromal cells from myelodysplastic syndromes,
acute myeloid leukemia with myelodysplasia-related changes, de novo acute myeloid leukemia and healthy donors.
Quantitative polymerase chain reaction analysis of CDKN1A (A) and TP53 (B) mRNA  expression in bone marrow
mesenchymal cells. The HPRT1 gene was used as an endogenous control and a healthy donor was used as a calibrator
sample. Horizontal lines indicate medians. *p-value <0.05, **p-value <0.01, ***p-value <0.001; ANOVA test and Bonferroni
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peciﬁc markers in BMMSC  studies. In the protocol used by Fei
t al.,4 BMMSCs were cultured in a special human mesenchy-
al  stem cell growth medium, while Pavlaki et al.5 cultured
MMSCs using DMEM.
With regard to the CDKN1A and TP53 expression proﬁle in
e novo AML  BMMSCs, our results corroborate the ﬁndings of
uvolo et al.,12 who  observed an upregulation of p21 and p53 in
MMSCs from AML, suggesting increased cellular senescence.
mportantly, our results highlight the biological and molecular
ifferences between AML-MRC and de novo AML reported by
ther research groups.13–15
Several lines of evidence indicate that alterations in the
one marrow niche contribute to the development and pro-
ression of MDS  and AML  and one of the most characterized
lements of the bone marrow niche is the BMMSCs.9,16 This
ell population represents a small fraction of bone marrow
ucleated cells, and a standardized protocol for isolation and
ulture of BMMSCs may be necessary to minimize experi-
ental variations and provide conclusive information about
he biology of these cells in these hematological malignan-
ies. Our results suggest that upregulation of CDKN1A and
P53 may indicate senescence of de novo AML  BMMSCs, which
ay contribute to the ineffective hematopoiesis found the this
isease.
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